Briumvi (ublituximab-xiiy) for the Treatment of Multiple Sclerosis, US
Briumvi™ (ublituximab-xiiy) is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Developed by US-based …